ASCO: Kite’s CAR-T passes lymphoma safety trial with flying colors
Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities occurring in patients with advanced B-cell lymphoma. The therapy was also tied to a complete response rate of 78% for patients receiving the highest cell therapy dose.
Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities occurring in patients with advanced B-cell lymphoma. The therapy was also tied to a complete response rate of 78% for patients receiving the highest cell therapy dose.
